Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reached a new 52-week low during trading on Monday . The stock traded as low as $7.40 and last traded at $7.46, with a volume of 16121 shares. The stock had previously closed at $7.48.
Several equities research analysts have commented on LXRX shares. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 3rd. BidaskClub downgraded Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, October 4th. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 28th. Citigroup dropped their target price on Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Finally, Gabelli reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $25.25.
The firm has a market cap of $792.32 million, a PE ratio of -5.91 and a beta of 0.73. The company has a quick ratio of 2.83, a current ratio of 2.90 and a debt-to-equity ratio of 8.85.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. The firm had revenue of $6.90 million for the quarter, compared to the consensus estimate of $12.56 million. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. The company’s quarterly revenue was down 74.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.29) earnings per share. As a group, equities analysts predict that Lexicon Pharmaceuticals, Inc. will post -1.29 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in the company. Tocqueville Asset Management L.P. purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at $164,000. Dynamic Technology Lab Private Ltd purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at $205,000. LPL Financial LLC increased its position in Lexicon Pharmaceuticals by 34.1% during the first quarter. LPL Financial LLC now owns 29,172 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 7,426 shares during the last quarter. MetLife Investment Advisors LLC increased its position in Lexicon Pharmaceuticals by 49.8% during the third quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock valued at $381,000 after acquiring an additional 11,862 shares during the last quarter. Finally, Tekla Capital Management LLC purchased a new stake in Lexicon Pharmaceuticals during the third quarter valued at $747,000.
About Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
See Also: Cost of Equity
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.